AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 122 min read$JANX

Janux Therapeutics, Inc. (JANX): Submission of Matters to a Vote of Security Holders

Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001817713 0001817713 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

Original reporting
SEC EDGAR 8-K
Published Jun 12, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$JANX
Neutral
high confidence
Mentioned
$JANX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JANXNeutralLow
01

Why it matters

Confirms governance items: two Class II directors elected, Ernst & Young LLP ratified as independent auditor for FY2026, and advisory approval of executive compensation.

02

Market read

This is a routine post-meeting disclosure; it does not introduce new operating, clinical, or financial information.

03

What to watch

Traders may instead focus on upcoming catalysts (e.g., trial readouts or financing) not covered in this 8-K.

Relevance 6/10Novelty 2/10Timing: Filed June 12, 2026 for June 11 annual meeting results

Background

The SEC 8-K (Item 5.07) reports matters submitted to a vote of security holders at Janux’s 2026 annual meeting on June 11, 2026.

Company-level read

Ticker impact

$JANXNeutralHigh confidence
Context

Janux Therapeutics filed an 8-K detailing 2026 annual meeting voting results, including director elections and advisory say-on-pay approval.

Expected impact

Low near-term impact; any reaction would be sentiment/flow-driven rather than fundamental.

Evidence & confidence

The filing reports election/ratification/advisory vote tallies without new financial guidance, clinical/regulatory updates, or transactions.

Market effects

Sector

Minimal; governance vote outcomes do not reset biotech sector risk or expectations.

Regional

None indicated; US-listed microcap governance filing only.

Global

None indicated.

Counterpoint

What could challenge this read

If the vote results were unusually contentious, it could hint at shareholder dissatisfaction, but the article provides no narrative on dissent beyond vote counts.

Key entities

  • issuer
    Janux Therapeutics, Inc.

    Company filing the 8-K and reporting annual meeting voting results.

  • director_candidate
    Natasha Hernday

    Elected as Class II director (votes for/withheld and broker non-votes reported).

  • director_candidate
    Eric Dobmeier

    Elected as Class II director (votes for/withheld and broker non-votes reported).

  • auditor
    Ernst & Young LLP

    Ratified by stockholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Read at source← All news

Related articles

AUG 6
$JANXMed

Janux Therapeutics, Inc. (JANX): Results of Operations and Financial Condition

Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 janx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study con

SEC EDGAR 8-K4 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min
AUG 8
$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.

simplywall.st6 min